Medtronic/$MDT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Ticker

$MDT
Sector

Primary listing

NYSE

Employees

95,000

Headquarters

Galway, Ireland

Medtronic Metrics

BasicAdvanced
$126B
27.03
$3.62
0.79
$2.81
2.90%

What the Analysts think about Medtronic

Analyst ratings (Buy, Hold, Sell) for Medtronic stock.

Bulls say / Bears say

Medtronic raised its fiscal 2026 profit forecast to $5.60–$5.66 per share, citing a lower-than-expected tariff impact of approximately $185 million, demonstrating operational resilience amid geopolitical uncertainties (Reuters).
The company reported Q1 FY26 revenue of $8.6 billion, up 8.4% as reported and 4.8% organically—its 11th consecutive quarter of mid-single-digit organic growth—driven by strength across its cardiovascular, neuroscience, surgical, and diabetes businesses (Ainvest).
Key innovation milestones—including CE Mark approval for its LigaSure RAS vessel-sealing technology on the Hugo robotic system and a proposed CMS National Coverage Determination for Symplicity Spyral hypertension therapy—signal Medtronic’s expanding pipeline of high-growth products (Ainvest).
The FDA classified its recall of Pipeline Vantage Embolization devices as the most serious (Class I), following reports of four patient deaths and thirteen injuries, highlighting significant liability and reputational risks (Reuters).
Newly imposed U.S. tariffs could raise Medtronic’s cost of goods sold by up to $950 million in fiscal 2026, and even after mitigating $600 million through supply-chain adjustments, the remaining headwind may compress margins (Barron’s).
Medtronic plans to spin off its $2.8 billion Diabetes division into a standalone public company within 18 months, introducing near-term execution risk and potentially removing a high-growth segment from its core portfolio (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

Medtronic Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Medtronic Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MDT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

FAQs